Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Bronchiolitis Epidemiology Forecast

DelveInsight’s ‘Bronchiolitis–Epidemiology Forecast—2030’ report delivers an in-depth understanding of Bronchiolitis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5
  • Japan

Study Period: 2018–2030

Bronchiolitis Disease Understanding

Bronchiolitis is most often described as a virus‐induced inflammation of small bronchioles and their surrounding tissue. Caused by respiratory viruses that invade the epithelial cells of the small airways, it begins with upper respiratory tract symptoms of rhinorrhoea followed by persistent cough, tachypnoea, chest wall recessions and widespread crackles, wheeze or both.

 

At pathologic examination, bronchiolitis is typically divided into two broad categories: cellular bronchiolitis and constrictive (fibrotic) bronchiolitis. Viruses are now known to be the prime cause of the syndrome and the associated characteristic pathology of the lower respiratory tract. The most common infectious agent causing acute bronchiolitis in children is the respiratory syncytial virus.

 

Bronchiolitis is mainly a clinical diagnosis. The diagnosis and severity of the illness should be made after eliciting a good history of present illness and based on the individual’s clinical manifestations. Treatment of bronchiolitis is supportive, and most individuals can be managed at home with hydration and comfort measures. Some cases with RSV lower respiratory infection present with critical hypoxemia, apnea, or respiratory failure and may immediately require intensive care.

Bronchiolitis Epidemiology

The Bronchiolitis epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Bronchiolitis epidemiology, segmented as incident cases of Bronchiolitis and incidence of Bronchiolitis by etiologies.The report includes the incident Bronchiolitis symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

 

The total 7MM incident cases of Bronchiolitis in 2020 was 8,026,904. Incident population of Bronchiolitis in 7MM is expected to increase at a CAGR of 0.01% for the study period 2018–2030.

Country-wise Bronchiolitis Epidemiology

The epidemiology segment also provides the Bronchiolitis epidemiology data and findings across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

The total incident cases of Bronchiolitis in 2020 were 4,031,966 in the United States.

Scope of the Report

  • Bronchiolitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Bronchiolitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Bronchiolitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • The report provides insight into the historical and forecasted patient pool of Bronchiolitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Bronchiolitis
  • The report provides the segmentation of the Bronchiolitis epidemiology by Prevalent Cases of Bronchiolitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • The report provides the segmentation of the Bronchiolitis epidemiology by severity-specific Prevalent Cases of Bronchiolitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan

Report Highlights

  • 10-year Forecast of Bronchiolitis epidemiology
  • United States Coverage
  • Total Prevalent Cases of Bronchiolitis
  • Prevalent Cases according to segmentation: Type-specific Prevalence of Bronchiolitis

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Bronchiolitis?
  • What are the key findings of Bronchiolitis epidemiology across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan and which type will have the highest number of patients during the forecast period (2018–2030)?
  • What would be the total number of patients with Bronchiolitis across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan during the forecast period (2018–2030)?
  • At what CAGR the patient population is expected to grow during the forecast period (2018–2030)?
  • What are the disease risk, burden, and unmet needs of Bronchiolitis?
  • What are the currently available treatments for Bronchiolitis?

Reasons to buy

The Bronchiolitis Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Bronchiolitis market
  • Quantify patient populations in the global Bronchiolitis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Bronchiolitis therapeutics in each of the markets covered
  • Understand the magnitude of Bronchiolitis population by its Prevalence cases
  • Understand the magnitude of Bronchiolitis population by its Type-specific cases
  • The Bronchiolitis epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Bronchiolitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Bronchiolitis Market Overview at a Glance

3.1. Market Share (%) Distribution of Bronchiolitis in 2018

3.2. Market Share (%) Distribution of Bronchiolitis in 2030

4. Executive Summary of Bronchiolitis

5. Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Pathophysiology of RSV Bronchiolitis

5.7. Clinical Manifestation

5.8. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Incident Patient Population of Bronchiolitis

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Incidence of Bronchiolitis

6.4.2. Incidence of Bronchiolitis by Etiologies

6.5. Germany

6.5.1. Incidence of Bronchiolitis

6.5.2. Incidence of Bronchiolitis by Etiologies

6.6. France

6.6.1. Incidence of Bronchiolitis

6.6.2. Incidence of Bronchiolitis by Etiologies

6.7. Italy

6.7.1. Incidence of Bronchiolitis

6.7.2. Incidence of Bronchiolitis by Etiologies

6.8. Spain

6.8.1. Incidence of Bronchiolitis

6.8.2. Incidence of Bronchiolitis by Etiologies

6.9. United Kingdom

6.9.1. Incidence of Bronchiolitis

6.9.2. Incidence of Bronchiolitis by Etiologies

6.10. Japan

6.10.1. Incidence of Bronchiolitis

6.10.2. Incidence of Bronchiolitis by Etiologies

7. Treatment and Management

8. Diagnostic and Treatment Guidelines

8.1. American Academy of Pediatrics (AAP) Guidelines 2014

8.2. National Institute for Health and Care Excellence (NICE) 2015 Guidelines

8.3. National Health Service (NHS) 2018 Guidelines

9. Patient Journey

10. Case Report

11. KOL Views

12. Appendix

12.1. Bibliography

12.2. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

15. About DelveInsight

List of Table

Table 1: Summary of Bronchiolitis, Market and Epidemiology (2018–2030)

Table 2: Incident Patient Population of Bronchiolitis in the 7MM (2018–2030)

Table 3: Incidence of Bronchiolitis in the US (2018–2030)

Table 4: Incidence of Bronchiolitis by Etiologies in the US (2018–2030)

Table 5: Incidence of Bronchiolitis in Germany (2018–2030)

Table 6: Incidence of Bronchiolitis by Etiology in Germany (2018–2030)

Table 7: Incidence of Bronchiolitis in France (2018–2030)

Table 8: Incidence of Bronchiolitis by Etiology in France (2018–2030)

Table 9: Incidence of Bronchiolitis in Italy (2018–2030)

Table 10: Incidence of Bronchiolitis by Etiology in Italy (2018–2030)

Table 11: Incidence of Bronchiolitis in Spain (2018–2030)

Table 12: Incidence of Bronchiolitis by Etiologies in Spain (2018–2030)

Table 13: Incidence of Bronchiolitis in the UK (2018–2030)

Table 14: Incidence of Bronchiolitis by Etiology in the UK (2018–2030)

Table 15: Incidence of Bronchiolitis in Japan (2018–2030)

Table 16: Incidence of Bronchiolitis by Etiology in Japan (2018–2030)

List of Figures

Figure 1: Classification of Bronchiolitis

Figure 2: Factors that Contribute to the Severity of Viral Bronchiolitis

Figure 3: Binding and Entry of RSV into the Host Cell

Figure 4: Factors Influencing the Pathogenesis and Clinical Disease Caused by RSV Infection in Infants and Young Children

Figure 5: Potential role of Neutophil in RSV Bronchiolitis

Figure 6: A schematic Model for Targeting Excessive Neutrophil Homeostasis and Function

Figure 7: Incidence of Bronchiolitis in the 7MM Countries (2018–2030)

Figure 8: Incidence of Bronchiolitis in the US (2018–2030)

Figure 9: Incidence of Bronchiolitis by Etiologies in the US (2018–2030)

Figure 10: Incidence of Bronchiolitis in Germany (2018–2030)

Figure 11: Incidence of Bronchiolitis by Etiologies in Germany (2018–2030)

Figure 12: Incidence of Bronchiolitis in France (2018–2030)

Figure 13: Incidence of Bronchiolitis by Etiologies in France (2018–2030)

Figure 14: Incidence of Bronchiolitis in Italy (2018–2030)

Figure 15: Incidence of Bronchiolitis by Etiologies in Italy (2018–2030)

Figure 16: Incidence of Bronchiolitis in Spain (2018–2030)

Figure 17: Incidence of Bronchiolitis by Etiologies in Spain (2018–2030)

Figure 18: Incidence of Bronchiolitis in the UK (2018–2030)

Figure 19: Incidence of Bronchiolitis by Etiologies in the UK (2018–2030)

Figure 20: Incidence of Bronchiolitis in Japan (2018–2030)

Figure 21: Incidence of Bronchiolitis by Etiologies in Japan (2018–2030)

Forward to Friend

Need A Quote